Tags

Type your tag names separated by a space and hit enter

Risperidone, an atypical antipsychotic enhances the antidepressant-like effect of venlafaxine or fluoxetine: possible involvement of alpha-2 adrenergic receptors.
Neurosci Lett. 2008 Nov 07; 445(1):83-8.NL

Abstract

Clinical studies have reported the beneficial outcome of addition of lower doses of risperidone to antidepressant therapy specifically with selective serotonin reuptake inhibitors (SSRIs) in the treatment of major depression. The present study, therefore, examined the beneficial effect, if any, of addition of risperidone (an atypical antipsychotic) to the antidepressant-like effect of venlafaxine (dual reuptake inhibitors of both serotonin and norepinephrine, SNRI) or fluoxetine (SSRI) in Porsolt's Forced Swim Test (FST) using male laca mice. Attempts have been made to study the involvement of alpha-2 adrenergic receptors in the mechanism of action. Immobility period was recorded for a period of 6 min. Venlafaxine (4 and 8 mg/kg, i.p.) or fluoxetine (10 and 20 mg/kg, i.p.) inhibited the immobility period in mice. Addition of risperidone (0.1 mg/kg, i.p.) potentiated the anti-immobility effect of either venlafaxine (4 and 8 mg/kg, i.p.) or fluoxetine (10 and 20 mg/kg, i.p.) in mouse FST. Furthermore, the anti-immobility effect of combination of risperidone (0.1 mg/kg, i.p) plus venlafaxine (4 mg/kg, i.p.) or fluoxetine (10 mg/kg, i.p.) was potentiated by the addition of yohimbine (2 mg/kg, i.p.), an alpha-2 adrenoceptors antagonist. The results of the present study suggest that the beneficial consequences of addition of risperidone with venlafaxine or fluoxetine in mouse forced swim test may involve alpha-2 adrenergic receptors.

Authors+Show Affiliations

Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh 160014, India.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18778754

Citation

Dhir, Ashish, and S K. Kulkarni. "Risperidone, an Atypical Antipsychotic Enhances the Antidepressant-like Effect of Venlafaxine or Fluoxetine: Possible Involvement of Alpha-2 Adrenergic Receptors." Neuroscience Letters, vol. 445, no. 1, 2008, pp. 83-8.
Dhir A, Kulkarni SK. Risperidone, an atypical antipsychotic enhances the antidepressant-like effect of venlafaxine or fluoxetine: possible involvement of alpha-2 adrenergic receptors. Neurosci Lett. 2008;445(1):83-8.
Dhir, A., & Kulkarni, S. K. (2008). Risperidone, an atypical antipsychotic enhances the antidepressant-like effect of venlafaxine or fluoxetine: possible involvement of alpha-2 adrenergic receptors. Neuroscience Letters, 445(1), 83-8. https://doi.org/10.1016/j.neulet.2008.08.074
Dhir A, Kulkarni SK. Risperidone, an Atypical Antipsychotic Enhances the Antidepressant-like Effect of Venlafaxine or Fluoxetine: Possible Involvement of Alpha-2 Adrenergic Receptors. Neurosci Lett. 2008 Nov 7;445(1):83-8. PubMed PMID: 18778754.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Risperidone, an atypical antipsychotic enhances the antidepressant-like effect of venlafaxine or fluoxetine: possible involvement of alpha-2 adrenergic receptors. AU - Dhir,Ashish, AU - Kulkarni,S K, Y1 - 2008/08/31/ PY - 2008/04/09/received PY - 2008/08/07/revised PY - 2008/08/27/accepted PY - 2008/9/10/pubmed PY - 2009/4/15/medline PY - 2008/9/10/entrez SP - 83 EP - 8 JF - Neuroscience letters JO - Neurosci Lett VL - 445 IS - 1 N2 - Clinical studies have reported the beneficial outcome of addition of lower doses of risperidone to antidepressant therapy specifically with selective serotonin reuptake inhibitors (SSRIs) in the treatment of major depression. The present study, therefore, examined the beneficial effect, if any, of addition of risperidone (an atypical antipsychotic) to the antidepressant-like effect of venlafaxine (dual reuptake inhibitors of both serotonin and norepinephrine, SNRI) or fluoxetine (SSRI) in Porsolt's Forced Swim Test (FST) using male laca mice. Attempts have been made to study the involvement of alpha-2 adrenergic receptors in the mechanism of action. Immobility period was recorded for a period of 6 min. Venlafaxine (4 and 8 mg/kg, i.p.) or fluoxetine (10 and 20 mg/kg, i.p.) inhibited the immobility period in mice. Addition of risperidone (0.1 mg/kg, i.p.) potentiated the anti-immobility effect of either venlafaxine (4 and 8 mg/kg, i.p.) or fluoxetine (10 and 20 mg/kg, i.p.) in mouse FST. Furthermore, the anti-immobility effect of combination of risperidone (0.1 mg/kg, i.p) plus venlafaxine (4 mg/kg, i.p.) or fluoxetine (10 mg/kg, i.p.) was potentiated by the addition of yohimbine (2 mg/kg, i.p.), an alpha-2 adrenoceptors antagonist. The results of the present study suggest that the beneficial consequences of addition of risperidone with venlafaxine or fluoxetine in mouse forced swim test may involve alpha-2 adrenergic receptors. SN - 0304-3940 UR - https://www.unboundmedicine.com/medline/citation/18778754/Risperidone_an_atypical_antipsychotic_enhances_the_antidepressant_like_effect_of_venlafaxine_or_fluoxetine:_possible_involvement_of_alpha_2_adrenergic_receptors_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0304-3940(08)01205-6 DB - PRIME DP - Unbound Medicine ER -